Pharmaceutical giant Merck delivered a strong performance on Thursday, comfortably topping Wall Street’s third-quarter revenue and earnings estimates while raising its full-year adjusted profit outlook. The positive results were propelled by stellar sales from its flagship cancer immunotherapy Keytruda—including its newer, rapidly growing injectable formulation—alongside solid demand for key vaccine and specialty products.
The robust quarterly report reflects a period of aggressive strategic maneuvering for the New Jersey-based drugmaker. As the pharmaceutical industry braces for the eventual loss of exclusivity on several of its top-selling products, Merck has engaged in an active deal spree and focused heavily on portfolio innovation. The company’s efforts to defend its dominant market positions and cultivate new growth drivers appear to be paying off, providing reassurance to investors concerned about upcoming patent cliffs.
Following the better-than-expected quarterly performance, Merck updated its financial guidance for the remainder of the year. The company now expects its full-year adjusted earnings to land between $2.77 and $2.82 per share. This revised outlook marks an upward adjustment from its previous projected range of $2.66 to $2.76 per share.
Crucially, the newly raised earnings guidance already accounts for a significant financial impact from external business development. The updated projections incorporate a one-time pre-tax charge of $400 million, or approximately 12 cents per share, which is tied directly to Merck’s recent exclusive global licensing agreement with SciBrunch, a China-based cancer drug developer focusing on innovative oncology treatments.
In addition to raising its profit expectations, Merck also adjusted its longer-term revenue projections. The company narrowed the lower end of its revenue guidance for 2026, announcing that it now anticipates total sales to fall between $66.8 billion and $67.3 billion. This compares favorably to its prior forecast, which had a lower threshold starting at $66.3 billion while maintaining the same $67.3 billion ceiling.
These financial adjustments arrive as Merck navigates a critical transition period. The company has been aggressively pursuing licensing deals, acquisitions, and pipeline expansions to offset the impending generic competition for Keytruda. The foundational patents for the blockbuster immunotherapy are scheduled to begin expiring in 2028, setting off a race within the company to establish alternative revenue streams and protected formulations.
A central pillar of this defensive and offensive growth strategy is Keytruda Qlex, a newer subcutaneous version of the drug administered as an under-the-skin injection rather than the traditional intravenous infusion. Merck has positioned Qlex as a cornerstone of its long-term strategy, aiming to transition patients smoothly from the original intravenous formulation to the more convenient injection format. By offering an alternative that improves patient experience and clinical administration efficiency, the company hopes to retain patients within its ecosystem and sustain Keytruda’s massive blockbuster sales well beyond the original product’s loss of exclusivity.
The strategy is already yielding tangible results. During the third quarter, Keytruda brought in an impressive $8.60 billion in total global sales, easily beating the $7.73 billion consensus estimate compiled by StreetAccount. Within that total, the Qlex formulation accounted for $830 million in sales, marking the highest quarterly figure recorded since the product was launched in 2025.
Market analysts had anticipated Qlex sales to reach roughly $649 million for the period, according to StreetAccount estimates. The substantial beat underscores the rapid adoption of the injectable version among oncologists and patients alike. This blowout quarter suggests that the new shot could eventually evolve into a multibillion-dollar product on an annual basis, providing a sturdy bridge across the looming patent expiration.
For the third quarter as a whole, Merck reported a net income of $5.07 billion, or $2.04 per share. This compares with a net income of $5.79 billion, or $2.32 per share, reported during the same period a year earlier. When excluding specific acquisition-related expenses and restructuring costs, Merck’s adjusted earnings came in at $2.49 per share. Total revenue for the quarter reached $18.09 billion, representing a solid 5% increase compared to the $17.22 billion generated in the corresponding period of the previous year.
Beyond the dominant performance of Keytruda, several of Merck’s newer products and core vaccine portfolios demonstrated robust growth during the quarter, helping to diversify the company’s revenue streams.
Winrevair, an innovative therapy utilized to treat pulmonary arterial hypertension—a rare and potentially deadly lung condition—continued its rapid commercial ascent. The specialty drug generated $694 million in sales for the third quarter, marking a remarkable 93% surge compared to the same period a year earlier and easily outpacing the $645 million that Wall Street analysts had expected.
Meanwhile, the Gardasil vaccine, designed to prevent cancers caused by the human papillomavirus, a very common sexually transmitted infection, delivered a strong rebound. The vaccine franchise drew approximately $2 billion in sales for the quarter, fueled primarily by higher demand within the United States market. This performance topped the $1.76 billion in sales anticipated by analysts.
The strong showing for Gardasil represents a welcome relief for Merck. Last year, the vaccine business had to grapple with elevated inventory levels in distribution channels and relatively weak demand in international markets, particularly in China. The recent quarter’s figures suggest that these inventory imbalances have largely been worked through, and domestic uptake has returned to a healthier trajectory.
Not every segment within the massive healthcare conglomerate outperformed expectations, however. Merck’s animal health division reported $1.68 billion in sales for the third quarter, coming in just slightly below the consensus estimates compiled by analysts, though the division remains a steady contributor to the company’s diversified business model.
With its latest financial disclosures, Merck has demonstrated that its core pharmaceutical blockbusters remain extraordinarily resilient, while newer formulations like Keytruda Qlex and high-growth specialty drugs like Winrevair are successfully picking up momentum. As the company continues to absorb licensing charges and invest heavily in its oncology and specialty pipelines, management’s upward revision of its profit outlook underscores a high level of confidence in navigating the competitive pharmaceutical landscape ahead.
